| 1 |
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
George W. Sledge, Masakazu Toi, Patrick Neven et al. · JAMA Oncology
Open access |
29 Sep 2019 |
1,016 |
| 2 |
Adherence to Therapies in Patients with Type 2 Diabetes
Luis‐Emilio García‐Pérez, María Daca-Álvarez, Tatiana Dilla et al. · Diabetes Therapy
Open access |
29 Aug 2013 |
744 |
| 3 |
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen R.D. Johnston, Miguel Martín, Angelo Di Leo et al. · npj Breast Cancer
Open access |
11 Jan 2019 |
693 |
| 4 |
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard H. Ludvik, Francesco Giorgino, Esteban Jódar et al. · The Lancet
|
Aug 2021 |
628 |
| 5 |
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
David L. Kendler, Fernando Marín, Cristiano A. F. Zerbini et al. · The Lancet
Open access |
9 Nov 2017 |
599 |
| 6 |
The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future
Steven M. Mennen et al. · Organic Process Research & Development
Open access |
7 May 2019 |
589 |
| 7 |
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs
Open access |
11 Jun 2014 |
576 |
| 8 |
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth J. Cusi, Laura Fernández Landó et al. · The Lancet Diabetes & Endocrinology
|
22 Apr 2022 |
500 |
| 9 |
Patient involvement in clinical research: why, when, and how
José Antonio Sacristán, Alfonso Aguarón, C. Avendaño et al. · Patient Preference and Adherence
Open access |
Apr 2016 |
382 |
| 10 |
Problems and solutions in calculating quality-adjusted life years (QALYs).
Luis Manuel Prieto, José Antonio Sacristán · Health and Quality of Life Outcomes
Open access |
2003 |
378 |
| 11 |
¿Qué es una tecnología sanitaria eficiente en España?
José Antonio Sacristán, Juan Oliva, J. del Llano et al. · Gaceta Sanitaria
Open access |
2002 |
361 |
| 12 |
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
Moritz Schütte et al. · Nature Communications
Open access |
10 Feb 2017 |
357 |
| 13 |
Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
Víctor Pérez, Inmaculada Gilaberte, Douglas E. Faries et al. · The Lancet
|
May 1997 |
302 |
| 14 |
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
Thomas J. Raub, Graham N. Wishart, Palaniappan Kulanthaivel et al. · Drug Metabolism and Disposition
|
6 Jul 2015 |
288 |
| 15 |
Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients
José Antonio Sacristán · BMC Medical Informatics and Decision Making
Open access |
8 Jan 2013 |
282 |
| 16 |
2-Amino-3-substituted-6-[(E)-1-phenyl-2-(N-methylcarbamoyl)vinyl]imidazo[1,2-a]pyridines as a Novel Class of Inhibitors of Human Rhinovirus: Stereospecific Synthesis and Antiviral Activity
Chafiq Hamdouchi, Jesús de Blas, Mirian del Prado et al. · Journal of Medicinal Chemistry
|
22 Dec 1998 |
280 |
| 17 |
Underdiagnosis of Attention-Deficit/Hyperactivity Disorder in Adult Patients
Ylva Ginsberg, Javier Quintero, Ernie Anand et al. · The Primary Care Companion For CNS Disorders
Open access |
12 Jun 2014 |
275 |
| 18 |
Classical Test Theory versus Rasch analysis for quality of life questionnaire reduction.
Luis Manuel Prieto, Jordi Alonso, Rosa Lamarca · Health and Quality of Life Outcomes
Open access |
2003 |
263 |
| 19 |
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Xueqian Gong et al. · Cancer Cell
Open access |
Dec 2017 |
243 |
| 20 |
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene
Xueqian Gong et al. · Cancer Discovery
|
29 Oct 2018 |
239 |
| 21 |
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Concepción Sánchez‐Martínez, Lawrence M. Gelbert, Marı́a José Lallena et al. · Bioorganic & Medicinal Chemistry Letters
Open access |
6 Jun 2015 |
238 |
| 22 |
Targeting the Synapse in Alzheimer’s Disease
Johanna Jackson, Enrique Jambrina, Jennifer Li et al. · Frontiers in Neuroscience
Open access |
23 Jul 2019 |
229 |
| 23 |
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
Sara A. Hurvitz, Miguel Martín, Michael F. Press et al. · Clinical Cancer Research
Open access |
15 Oct 2019 |
227 |
| 24 |
Metallaphotoredox-Catalyzed Cross-Electrophile C sp 3 –C sp 3 Coupling of Aliphatic Bromides
Russell T. Smith, Xiaheng Zhang, Juan A. Rincón et al. · Journal of the American Chemical Society
Open access |
5 Dec 2018 |
225 |
| 25 |
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
Concepción Sánchez‐Martínez, Marı́a José Lallena, Sonia Gutiérrez Sanfeliciano et al. · Bioorganic & Medicinal Chemistry Letters
Open access |
26 Aug 2019 |
212 |
| 26 |
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Raquel Torres-Guzmán, Bruna Calsina, Ana Hermoso et al. · Oncotarget
Open access |
10 May 2017 |
202 |
| 27 |
Worse Quality of Life for Children With Newly Diagnosed Attention-Deficit/Hyperactivity Disorder, Compared With Asthmatic and Healthy Children
Rodrigo Renda de Escobar, César A. Soutullo, Amaia Hervás et al. · PEDIATRICS
|
Sep 2005 |
189 |
| 28 |
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
Miguel Martín, Amparo Ruı́z, Monserrat Muñoz et al. · The Lancet Oncology
|
17 Feb 2007 |
187 |
| 29 |
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Hope S. Rugo, Jens Huober, José Á. García-Sáenz et al. · The Oncologist
Open access |
21 Sep 2020 |
182 |
| 30 |
Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study
Josep María Haro, Diego Novick, Jordan Bertsch et al. · The British Journal of Psychiatry
Open access |
Sep 2011 |
178 |
| 31 |
A Randomized Double-Blind Study of Atomoxetine Versus Placebo for Attention-Deficit/Hyperactivity Disorder Symptoms in Children With Autism Spectrum Disorder
Myriam Harfterkamp, Gigi van de Loo-Neus, Ruud B. Minderaa et al. · Journal of the American Academy of Child & Adolescent Psychiatry
Open access |
25 May 2012 |
172 |
| 32 |
Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures
Karsten Boehnke, Philip W. Iversen, Dirk Schumacher et al. · SLAS DISCOVERY
Open access |
27 May 2016 |
152 |
| 33 |
Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Glen J. Weiss, Corey Jay Langer, Rafael Rosell et al. · Journal of Clinical Oncology
Open access |
18 Sep 2006 |
148 |
| 34 |
Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room
Alonso G. Montoya, Amparo Valladares, Luís Lizán et al. · Health and Quality of Life Outcomes
Open access |
2011 |
141 |
| 35 |
Twice‐daily pre‐mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes
James K. Malone, Shuang Bai, Barbara N. Campaigne et al. · Diabetic Medicine
|
21 Mar 2005 |
140 |
| 36 |
Is psychoeducation for parents and teachers of children and adolescents with ADHD efficacious? A systematic literature review
Alonso G. Montoya, Francesc Colom, Meredith Ferrin · European Psychiatry
Review |
3 Feb 2011 |
137 |
| 37 |
Major depressive disorder in Latin America: The relationship between depression severity, painful somatic symptoms, and quality of life
RODRIGO A. MUNOZ, Margaret E. McBride, Alan J. M. Brnabic et al. · Journal of Affective Disorders
|
3 Mar 2005 |
131 |
| 38 |
Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: Prevalence and associations in a cross-sectional study
Luis San, Antonio Ciudad, Enric Álvarez et al. · European Psychiatry
|
2 Oct 2007 |
128 |
| 39 |
Structural determinants of dual incretin receptor agonism by tirzepatide
Bingfa Sun et al. · Proceedings of the National Academy of Sciences
Open access |
25 Mar 2022 |
127 |
| 40 |
Acromegaly Quality of Life Questionnaire (AcroQoL).
Xavier Costa Badia, Susan M. Webb, Luís Prieto et al. · Health and Quality of Life Outcomes
Open access |
2004 |
127 |
| 41 |
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Robert M. Campbell et al. · Molecular Cancer Therapeutics
|
19 Dec 2013 |
124 |
| 42 |
Adherencia y persistencia terapéutica: causas, consecuencias y estrategias de mejora
Tatiana Dilla, Amparo Valladares, Luís Lizán et al. · Atención Primaria
Open access |
Jun 2009 |
120 |
| 43 |
Selection of heterocycles for drug design
Howard B. Broughton, Ian A. Watson · Journal of Molecular Graphics and Modelling
|
12 May 2004 |
119 |
| 44 |
Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties
Mary M. Mader et al. · Bioorganic & Medicinal Chemistry Letters
Open access |
14 Nov 2007 |
117 |
| 45 |
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial
Piet Geusens, Fernando Marín, David L. Kendler et al. · Journal of Bone and Mineral Research
Open access |
12 Jan 2018 |
115 |
| 46 |
Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study
Carmen Turbí, Gabriel Herrero‐Beaumont, J.C. Acebes et al. · Clinical Therapeutics
|
Feb 2004 |
108 |
| 47 |
Factor analysis of the Zung self-rating depression scale in a large sample of patients with major depressive disorder in primary care
Irene Romera, Helena Delgado-Cohen, Teresa Pérez et al. · BMC Psychiatry
Open access |
14 Jan 2008 |
107 |
| 48 |
Raloxifene: Mechanism of Action, Effects on Bone Tissue, and Applicability in Clinical Traumatology Practice
José Ramón Caeiro Rey, Eduardo Vaquero Cervino, María Luz Rentero et al. · The Open Orthopaedics Journal
Open access |
20 Feb 2009 |
104 |
| 49 |
A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
Tinggui Yin et al. · Molecular Cancer Therapeutics
Open access |
Apr 2014 |
104 |
| 50 |
Prevalencia del síndrome metabólico (criterios del ATP-III). Estudio de base poblacional en áreas rural y urbana de la provincia de Segovia
Nicholas G. Martin, Cristina Fernández, José Luis González‐Sánchez et al. · Medicina Clínica
|
Oct 2005 |
102 |